AKT1 and female reproductive organ cancer: The mPFS for the ER-positive breast cancer, gynecologic cancer, and other solid tumor cohorts with AKT1-E17K-m (N=20, 15 and 17) were 5.5 months (95% CI, 2.9-6.9), 6.6 months (95% CI, 1.5-8.3), and 4.2 months (95% CI, 2.1-12.8), respectively.